(BN) Danone - Overview
Sector: Consumer Defensive | Industry: Packaged Foods | Exchange: PA (France) | Market Cap: 42.994m EUR | Total Return: -2.4% in 12m
Stock
Dairy, Plant-Based, Baby Food, Water
Total Rating 55
Safety 84
Buy Signal -0.07
Market Cap:
49,830m
Avg Trading Vol: 105M EUR
Avg Trading Vol: 105M EUR
ATR:
2.25%
Peers RS (IBD): 57.7
Peers RS (IBD): 57.7
Risk 5d forecast
Volatility20.2%
Rel. Tail Risk-10.4%
Reward TTM
Sharpe Ratio-0.10
Alpha2.05
Character TTM
Beta-0.255
Beta Downside-0.267
Drawdowns 3y
Max DD17.29%
CAGR/Max DD0.51
Description: BN Danone
Danone S.A. (BN) is a global food and beverage company with operations across Europe, North America, Asia, Africa, and Latin America. The company operates within the Packaged Foods & Meats sub-industry, a sector characterized by consumer staples with relatively stable demand.
Danones business model is diversified across three primary segments: Essential Dairy & Plant-Based, Specialized Nutrition, and Waters. This multi-segment approach allows Danone to cater to a broad consumer base, from everyday dairy and plant-based products to specialized medical nutrition. The company utilizes a wide range of distribution channels, including retail, e-commerce, and healthcare providers.
Danones extensive brand portfolio includes well-known names such as Actimel, Activia, Alpro, Aptamil, evian, and Volvic. This brand strength is a key asset in the competitive food and beverage market, which often relies on consumer loyalty and product recognition.
For a deeper dive into Danones financial performance and valuation metrics, consider exploring the data available on ValueRay.
- Dairy and plant-based sales growth impacts revenue
- Specialized nutrition demand drives profit margins
- Water segment performance influences overall sales
- Input cost fluctuations affect profitability
- Regulatory changes in food and beverage markets pose risks
Piotroski VR‑10 (Strict)
7.0
| Net Income: 3.85b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 2.06 > 1.0 |
| NWC/Revenue: -2.55% < 20% (prev -1.90%; Δ -0.66% < -1%) |
| CFO/TA 0.17 > 3% & CFO 7.61b > Net Income 3.85b |
| Net Debt (13.14b) to EBITDA (7.40b): 1.78 < 3 |
| Current Ratio: 0.90 > 1.5 & < 3 |
| Outstanding Shares: last quarter (645.1m) vs 12m ago 0.51% < -2% |
| Gross Margin: 50.16% > 18% (prev 0.47%; Δ 4.97k% > 0.5%) |
| Asset Turnover: 122.1% > 50% (prev 108.0%; Δ 14.11% > 0%) |
| Interest Coverage Ratio: 4.95 > 6 (EBITDA TTM 7.40b / Interest Expense TTM 1.32b) |
Altman Z''
2.63
| A: -0.03 (Total Current Assets 13.23b - Total Current Liabilities 14.62b) / Total Assets 45.07b |
| B: 0.41 (Retained Earnings 18.58b / Total Assets 45.07b) |
| C: 0.15 (EBIT TTM 6.54b / Avg Total Assets 44.78b) |
| D: 0.48 (Book Value of Equity 13.47b / Total Liabilities 28.10b) |
| Altman-Z'' Score: 2.63 = A |
Beneish M
-3.14
| DSRI: 0.92 (Receivables 3.04b/2.92b, Revenue 54.66b/48.03b) |
| GMI: 0.94 (GM 50.16% / 46.90%) |
| AQI: 1.00 (AQ_t 0.56 / AQ_t-1 0.56) |
| SGI: 1.14 (Revenue 54.66b / 48.03b) |
| TATA: -0.08 (NI 3.85b - CFO 7.61b) / TA 45.07b) |
| Beneish M-Score: -3.14 (Cap -4..+1) = AA |
What is the price of BN shares?
As of April 06, 2026, the stock is trading at EUR 69.24 with a total of 1,100,091 shares traded.
Over the past week, the price has changed by +3.10%, over one month by -1.00%, over three months by -6.94% and over the past year by -2.40%.
Over the past week, the price has changed by +3.10%, over one month by -1.00%, over three months by -6.94% and over the past year by -2.40%.
Is BN a buy, sell or hold?
Danone has no consensus analysts rating.
What are the forecasts/targets for the BN price?
| Wallstreet Target Price | 79.6 | 14.9% |
| Analysts Target Price | - | - |
BN Fundamental Data Overview
as of 05 April 2026
Market Cap USD = 49.83b (42.99b EUR * 1.159 EUR.USD)P/E Trailing = 23.8156
P/E Forward = 17.6056
P/S = 1.5759
P/B = 2.5922
P/EG = 1.7096
Revenue TTM = 54.66b EUR
EBIT TTM = 6.54b EUR
EBITDA TTM = 7.40b EUR
Long Term Debt = 9.76b EUR (from longTermDebt, last quarter)
Short Term Debt = 5.04b EUR (from shortTermDebt, last quarter)
Debt = 15.12b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.14b EUR (from netDebt column, last quarter)
Enterprise Value = 51.54b EUR (42.99b + Debt 15.12b - CCE 6.57b)
Interest Coverage Ratio = 4.95 (Ebit TTM 6.54b / Interest Expense TTM 1.32b)
EV/FCF = 9.15x (Enterprise Value 51.54b / FCF TTM 5.63b)
FCF Yield = 10.93% (FCF TTM 5.63b / Enterprise Value 51.54b)
FCF Margin = 10.30% (FCF TTM 5.63b / Revenue TTM 54.66b)
Net Margin = 7.03% (Net Income TTM 3.85b / Revenue TTM 54.66b)
Gross Margin = 50.16% ((Revenue TTM 54.66b - Cost of Revenue TTM 27.24b) / Revenue TTM)
Gross Margin QoQ = 50.33% (prev 50.90%)
Tobins Q-Ratio = 1.14 (Enterprise Value 51.54b / Total Assets 45.07b)
Interest Expense / Debt = 0.90% (Interest Expense 136.0m / Debt 15.12b)
Taxrate = 32.06% (368.0m / 1.15b)
NOPAT = 4.45b (EBIT 6.54b * (1 - 32.06%))
Current Ratio = 0.90 (Total Current Assets 13.23b / Total Current Liabilities 14.62b)
Debt / Equity = 0.89 (Debt 15.12b / totalStockholderEquity, last quarter 16.92b)
Debt / EBITDA = 1.78 (Net Debt 13.14b / EBITDA 7.40b)
Debt / FCF = 2.33 (Net Debt 13.14b / FCF TTM 5.63b)
Total Stockholder Equity = 16.83b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.59% (Net Income 3.85b / Total Assets 45.07b)
RoE = 22.85% (Net Income TTM 3.85b / Total Stockholder Equity 16.83b)
RoCE = 24.61% (EBIT 6.54b / Capital Employed (Equity 16.83b + L.T.Debt 9.76b))
RoIC = 18.56% (NOPAT 4.45b / Invested Capital 23.95b)
WACC = 3.94% (E(42.99b)/V(58.11b) * Re(5.11%) + D(15.12b)/V(58.11b) * Rd(0.90%) * (1-Tc(0.32)))
Discount Rate = 5.11% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 33.33 | Cagr: 0.25%
[DCF] Terminal Value 88.19% ; FCFF base≈5.24b ; Y1≈6.28b ; Y5≈10.05b
[DCF] Fair Price = 436.4 (EV 292.51b - Net Debt 13.14b = Equity 279.37b / Shares 640.2m; r=6.0% [WACC]; 5y FCF grow 21.33% → 3.0% )
EPS Correlation: -3.75 | EPS CAGR: -31.64% | SUE: 0.0 | # QB: 0
Revenue Correlation: 55.09 | Revenue CAGR: 30.68% | SUE: -0.02 | # QB: 0
EPS current Year (2026-12-31): EPS=3.93 | Chg7d=+0.002 | Chg30d=-0.020 | Revisions Net=-16 | Growth EPS=+3.5% | Growth Revenue=+2.7%
EPS next Year (2027-12-31): EPS=4.24 | Chg7d=-0.004 | Chg30d=-0.018 | Revisions Net=-11 | Growth EPS=+7.8% | Growth Revenue=+4.0%
[Analyst] Revisions Ratio: -0.89 (1 Up / 17 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 3.7% (Discount Rate 7.9% - Earnings Yield 4.2%)
[Growth] Growth Spread = +0.3% (Analyst 4.0% - Implied 3.7%)